Pages that link to "Q35267370"
Jump to navigation
Jump to search
The following pages link to Cladribine (2-chlorodeoxyadenosine) (Q35267370):
Displaying 50 items.
- Neurodegeneration in multiple sclerosis: novel treatment strategies (Q22241472) (← links)
- New and emerging disease modifying therapies for multiple sclerosis (Q22242305) (← links)
- Multiple sclerosis: the role of cytokines in pathogenesis and in therapies (Q27011014) (← links)
- Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis (Q28281816) (← links)
- Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria (Q28362384) (← links)
- Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c (Q28368340) (← links)
- Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone (Q28377894) (← links)
- Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse (Q33328157) (← links)
- Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas (Q33330233) (← links)
- Cladribine in the treatment of chronic lymphocytic leukemia (Q33337860) (← links)
- Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study (Q33363695) (← links)
- Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation? (Q33390319) (← links)
- Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma (Q33499947) (← links)
- Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma (Q33504540) (← links)
- Promising treatments of tomorrow for multiple sclerosis (Q33670947) (← links)
- Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies (Q33991278) (← links)
- Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study (Q34053766) (← links)
- Nucleoside analogues and nucleobases in cancer treatment. (Q34141323) (← links)
- Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved (Q34153221) (← links)
- Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis (Q34184148) (← links)
- Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies (Q34290943) (← links)
- Nucleoside analogues in the treatment of haematological malignancies (Q34390281) (← links)
- Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice (Q34441015) (← links)
- Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy (Q34629345) (← links)
- The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials (Q34632502) (← links)
- Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia (Q34662884) (← links)
- Oral disease-modifying therapies for multiple sclerosis (Q34996562) (← links)
- Development of oral cladribine for the treatment of multiple sclerosis (Q35013390) (← links)
- The cladribine conundrum: deciphering the drug's mechanism of action (Q35016421) (← links)
- Cladribine in the treatment of hairy-cell leukaemia (Q35096781) (← links)
- Purine nucleoside analogues in the treatment of myleoid leukemias (Q35104351) (← links)
- Multiple sclerosis: pathogenesis and treatment (Q35151851) (← links)
- Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies (Q35562656) (← links)
- Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis (Q35606563) (← links)
- Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone (Q35818224) (← links)
- Cladribine: from the bench to the bedside--focus on hairy cell leukemia (Q35918435) (← links)
- Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). (Q35994964) (← links)
- Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies (Q36057860) (← links)
- Cladribine for multiple sclerosis: review and current status (Q36307847) (← links)
- Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies (Q36346370) (← links)
- Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity (Q36378036) (← links)
- My Treatment Approach to Hairy Cell Leukemia (Q36399120) (← links)
- Cladribine: an investigational immunomodulatory agent for multiple sclerosis (Q36598122) (← links)
- Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies (Q36617540) (← links)
- Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine (Q36748692) (← links)
- Oral disease-modifying treatments for multiple sclerosis: the story so far. (Q36830152) (← links)
- Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market (Q36903606) (← links)
- The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia (Q36948475) (← links)
- Immunosuppressive agents in multiple sclerosis (Q36963189) (← links)
- Cladribine in indolent non-Hodgkin's lymphoma (Q37134422) (← links)